Evidence map›Paper›PMID 28235058›Full record

ArticlePloS one2017

Cardiovascular disease risk prediction by the American College of Cardiology (ACC)/American Heart Association (AHA) Atherosclerotic Cardiovascular Disease (ASCVD) risk score among HIV-infected patients in sub-Saharan Africa.

Mosepele Mosepele, Linda C Hemphill, Tommy Palai, Isaac Nkele, Kara Bennett, Shahin Lockman, Virginia A Triant

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Optimized Clinical Feature Analysis for Improved Cardiovascular Disease Risk Screening.IEEE open journal of engineering in medicine and biology · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Mosepele MosepeleDepartment of Medicine, Faculty of Medicine, University of Botswana, Gaborone, Botswana.ORCID http://orcid.org/0000-0002-6051-0999
Linda C HemphillThe Heart Center, Division of Cardiology, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts, United States of America.
Tommy PalaiDepartment of Medicine, Faculty of Medicine, University of Botswana, Gaborone, Botswana.
Isaac NkeleBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Kara BennettBennett Statistical Consulting Inc, Ballston Lake, New York, United States of America.
Shahin LockmanBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Virginia A TriantDivision of General Internal Medicine & Division of Infectious Diseases, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts, United States of America.
Harvard University · USUniversity of Botswana · BWBotswana Harvard AIDS Institute Partnership · BWBrigham and Women's Hospital · US

Funding

Optimizing Cardiovascular Risk Prediction in HIVR01HL132786 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI D'AGOSTINO, RALPH B, TRIANT, VIRGINIA ATHENA · 2017 to 2020
$3.5M
Evaluation and development of cardiovascular risk prediction algorithms in HIVR56HL125029 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI TRIANT, VIRGINIA ATHENA · 2014 to 2014
$821k
Statin Use and Efficacy Among HIV-Infected Patients by Cholesterol Risk CategoryR21HL122138 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI TRIANT, VIRGINIA ATHENA · 2014 to 2015
$259k
NHLBI NIH HHS R01 HL132786NHLBI NIH HHS R21 HL122138NHLBI NIH HHS R56 HL125029
6 · The paper itself

Abstract

objectivesHIV-infected patients are at increased risk for cardiovascular disease (CVD). However, general population CVD risk prediction equations that identify HIV-infected patients at elevated risk have not been widely assessed in sub-Saharan African (SSA).

methodsHIV-infected adults from 30-50 years of age with documented viral suppression were enrolled into a cross-sectional study in Gaborone, Botswana. Participants were screened for CVD risk factors. Bilateral carotid intima-media thickness (cIMT) was measured and 10-year predicted risk of cardiovascular disease was calculated using the Pooled Cohorts Equation for atherosclerotic CVD (ASCVD) and the 2008 Framingham Risk Score (FRS) (National Cholesterol Education Program III-NCEP III). ASCVD ≥7.5%, FRS ≥10%, and cIMT≥75th percentile were considered elevated risk for CVD. Agreement in classification of participants as high-risk for CVD by cIMT and FRS or ASCVD risk score was assessed using McNemar`s Test. The optimal cIMT cut off-point that matched ASCVD predicted risk of ≥7.5% was assessed using Youden's J index.

resultsAmong 208 HIV-infected patients (female: 55%, mean age 38 years), 78 (38%) met criteria for ASCVD calculation versus 130 (62%) who did not meet the criteria. ASCVD classified more participants as having elevated CVD risk than FRS (14.1% versus 2.6%, McNemar's exact test p = 0.01), while also classifying similar proportion of participants as having elevated CVD like cIMT (14.1% versus 19.2%, McNemar's exact test p = 0.34). Youden's J calculated the optimal cut point at the 81st percentile for cIMT to correspond to an ASCVD score ≥7.5% (sensitivity = 72.7% and specificity = 88.1% with area under the curve for the receiver operating characteristic [AUC] of 0.82, 95% Mann-Whitney CI: 0.66-0.99).

conclusionWhile the ASCVD risk score classified more patients at elevated CVD risk than FRS, ASCVD score classified similar proportion of patients as high risk when compared with established subclinical atherosclerosis. However, potential CVD risk category misclassification by established equations such as ASCVD may still exist among HIV-infected patients; hence there is still a need for development of a CVD risk prediction equation tailored to HIV-infected patients in SSA.

Indexed as

AdultAfrica South of the SaharaAmerican Heart AssociationAtherosclerosisCross-Sectional StudiesHIV InfectionsHumansMaleMiddle AgedPilot ProjectsRisk AssessmentUnited States

Identifiers

PMID28235058
PMCPMC5325544
OpenAlexW2591016704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.